GET DAILY SIGNALSAlcon (ALC) Readies Q3 2026 Earnings: Key Metrics and Investor Focus Areas
Key Takeaways
- Alcon Inc. (ALC) is scheduled to report its third-quarter 2026 results on Tuesday, November 10, 2026, after the market close, followed by a conference call on November 11.
- Wall Street consensus points to earnings per share (EPS) of roughly $0.89, compared with $0.79 in the prior-year quarter.
- Analysts expect revenue of approximately $2.7 billion, up mid-single digits from $2.59 billion a year earlier.
- Investors are focused on traction from new product launches and whether rising competition in premium intraocular lenses (IOLs, or lenses implanted during cataract surgery) is pressuring market share.
- Full-year 2026 guidance and any update on core operating margins will be closely watched.
- Alcon has beaten consensus EPS in six of its last eight quarters, most recently topping estimates in the second quarter of 2026.
Earnings Context and Its Significance
Alcon stands as the world’s largest eye-care device company and finds itself in the midst of a substantial product cycle across its Surgical and Vision Care segments. The upcoming third-quarter report matters because it will reveal whether recent introductions such as the Unity VCS and Unity CS surgical platforms, PanOptix Pro intraocular lenses, the Tryptyr dry-eye treatment, and Precision7 contact lenses are driving revenue growth and market-share improvements. This update comes as competition intensifies in premium IOLs from companies including Johnson & Johnson Vision and Bausch + Lomb. With the stock essentially flat year to date and trailing the broader Swiss market, investors seek signs that the innovation pipeline can maintain momentum and protect Alcon’s leading position. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What Analysts Are Expecting
For the third quarter of 2026, analysts anticipate core EPS of approximately $0.89, representing growth of about 13% from $0.79 in the same period last year. Consensus revenue sits near $2.7 billion, indicating mid-single-digit expansion from $2.59 billion in the prior-year quarter. These projections suggest a modest sequential decline from the second quarter, when Alcon delivered EPS of $0.84 and revenue of $2.82 billion, both exceeding estimates. The company’s full-year 2026 outlook includes revenue growth of 5% to 7% in constant currencies, core operating margin expansion of 90 to 190 basis points, and core EPS growth of 12% to 15% in constant currencies, alongside a projected net tariff impact of $40 million to $90 million. Investors will monitor gross margin trends and any adjustments to this guidance.
Market Sentiment Ahead of the Report
Sentiment into the release appears cautiously optimistic yet mixed. Analysts have raised EPS estimates modestly over the past 60 days while lowering revenue expectations, reflecting confidence in profitability amid a tougher revenue environment. In the second quarter, Alcon exceeded EPS estimates by roughly 10%, which supported optimism around execution. Still, the stock has posted only modest year-to-date gains, closing near $75 ahead of the announcement, well below its 52-week high of about $87. Potential risks include slower adoption of new products, continued pricing pressure in premium IOLs, and any downward revision to full-year margin guidance. A notable price reaction could follow the release, especially if management provides an updated outlook.
What to Watch Going Forward
Beyond the headline numbers, investors should pay attention to how management discusses the remainder of 2026. The first quarter showed roughly 10% reported sales growth helped by favorable comparisons, raising the question of whether that pace can continue as tougher year-over-year baselines emerge. Margin performance remains a key theme. With gross margin near 57%, Alcon needs to demonstrate pricing power and operating leverage while managing launch costs and input-cost pressures. Any comments on full-year core operating margin targets will indicate management’s confidence in the profitability of its new offerings. The competitive landscape in implantable lenses also warrants focus. The overall market continues to expand, with premium products gaining share, yet Alcon must show it can hold its ground against Johnson & Johnson and Bausch + Lomb. Confirmation of full-year guidance, sustained contact-lens growth, and steady progress in the ocular-health franchise would likely reassure investors that the product cycle stays on track.
Using Tickeron’s AI Tools for Earnings Research
In preparing for this earnings season, I turned to Tickeron’s AI Screener to quickly filter peers in the medical devices space and compare recent performance trends. The tool allowed me to apply custom criteria around revenue growth, margin expansion, and technical signals, which helped surface relevant context without manual data crunching. It proved useful for organizing thoughts ahead of Alcon’s report and similar upcoming releases.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for ALC turns positive, indicating new upward trend
ALC saw its Momentum Indicator move above the 0 level on October 15, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In 60 of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at 66%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ALC just turned positive on October 09, 2026. Looking at past instances where ALC's MACD turned positive, the stock continued to rise in 33 of 53 cases over the following month. The odds of a continued upward trend are 62%.
ALC moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ALC crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 60%.
Following a +3.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALC advanced for three days, in 175 of 311 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
Bearish Trend Analysis
The 10-day RSI Indicator for ALC moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 13 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 50%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 16 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
ALC broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALC entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. ALC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.678) is normal, around the industry mean (4.964). P/E Ratio (56.773) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (1.165) is also within normal values, averaging (4.143). Dividend Yield (0.014) settles around the average of (0.005) among similar stocks. P/S Ratio (2.996) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer and manufacturer of surgical & eye care device
Industry PharmaceuticalsOther
Advertisement